New drug GB18 targets wasting in cancer patients – first human trial launches
Disease control
Recruiting now
This early-stage trial tests a new drug called GB18, designed to treat cancer cachexia—a condition where cancer patients lose weight and muscle. The study involves 36 healthy adults to check the drug's safety and how the body processes it. Participants receive a single injection …
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC